Jim Mazzo, Executive Chairman, Neurotech, Advisor, ZEISS, Advisor, Bain - Fri, 10/23 at 8 AM {CLOSED}
Topic | Buying and Selling Healthcare Companies
James V. (Jim) Mazzo is Global President for Carl Zeiss Meditec’s Strategic Business Unit Ophthalmic Devices, which includes Ophthalmic Diagnostics, Surgical Ophthalmology and Refractive Lasers. Carl Zeiss Meditec has the broadest line of diagnostic and surgical products in the industry and has been an innovative leader in medical technology for over 100 years.
Mazzo is one of the ophthalmic industry’s best known and most respected business leaders with over 38 years of proven experience. His global reputation for building and running world-class organizations is based on 22 years leading Allergan’s North American and European eye care organizations; 7 years as Chairman, President and CEO of Advanced Medical Optics (AMO); 4 years as EVP of Abbott’s global ophthalmology business; 3 years as Executive Chair and CEO of AcuFocus.
Additionally, he is Chairman of Neurotech, a retinal implant company; on the Board of Directors for Avellino Labs, a biotechnology and genetic science company; and is founder and Chairman of Octane. He is a member of the International Intraocular Implant Club (lllC), is Leerink’s Special Advisor Medical Devices and is Executive Committee Board Member with the Medical Device Manufacturers Association (MDMA). Mazzo is on the ASCRS Governing Board, the AAO Foundation Advisory Board, the ICO Foundation Advisory Board, the AGS Foundation Advisory Board, a Chair Member of the Gavin Herbert Eye Institute, a Board Member of the Anaheim Ducks Foundation, serves on NASA’s Mission to Mars Committee and is an Officer in the Order of St. John.
His accomplishments and contributions to the healthcare industry and business and educational communities include serving as Board Chairman for AdvaMed; on the University of California at Irvine foundation; as Vice Chair Trustee Chapman University; as past trustee for University of San Diego; and recognized two times on The Ophthalmologist’s Power List as a top influencer in ophthalmology today.
Eric Paul Rose, MBA, President, Pinnacle Product Innovation , Inc. - Mon, 10/26 at 8 AM {CLOSED}
Topic | 3 Keys to Successful New Products
This talk breaks down the chaotic product innovation process into three simple Keys. These "3 Keys" in priority order are; Marketability, Technical Feasibility, and Protectability. Eric spends a significant portion of time covering Marketability, since 42% of ventures that fail, fail for lack of creating a product the market values. He also covers the other two Keys, Technical Feasibility and Protectability. This talk is particularly well suited for those who are looking to expand their knowledge of new product innovation and the commercialization process.
Georgette Pascale, Founder & CEO, Pascale Communications - Wed, 10/26 at 8 AM {CLOSED}
Topic | Marketing in Coronatime: How to stay authentic and tools for success
A highly motivated entrepreneur/ philanthropist with varied public relations/ digital communications experience across many areas. Healthcare is my current love. I thrive on networking, mentoring, new business initiatives and partnerships, strategic thinking, crisis management and supporting the amazing Pascāle team.
Keith Holliday, Chief Technology Officer, STAAR Surgical - Tues, 10/27 at 8 AM {CLOSED}
Topic | Taxes, death and presbyopia: all are certain but only one can be treated – recent advances in the field
Dr. Keith Holliday joined STAAR Surgical in August 2015 and holds the position of Chief Technology Officer, leading the company’s Research and Development program. The most recent new product to have emerged from STAAR’s Technology Center in Tustin is the EVO Viva Implantable Collamer Lens with Aspheric (EDOF) Optic, designed to correct presbyopia (CE Mark approval but not approved in the USA). From 2007 to his arrival at STAAR, he served as Vice President, Research and Development at ReVision Optics where he oversaw the development of a novel technology for presbyopia correction, as well as managing first-in-man clinical studies. Previously, he was Director of Laser Technology at Advanced Medical Optics (AMO) and Staff Laser Scientist at VISX, in both roles working on advances in LASIK technology. Prior to joining VISX, Dr. Holliday worked primarily in academia. He obtained his first degree in Physics and Electronics from the University of St. Andrews in Scotland and a Ph.D. from the Laser Physics Centre at the Australian National University. He spent three years at the Swiss Federal Institute of Technology, where he was primarily involved with the utilization of optically active polymers and crystals to develop materials and techniques for very high density, holographic optical storage and computational systems. Dr. Holliday holds patents in excimer laser beam detection, control and profiling, methods to correct presbyopia that synergistically take into account the epithelium’s response to changes in corneal shape, and optical materials. He has also authored 37 peer reviewed publications in the scientific literature plus two book chapters and one single-authored book. He is considered an expert on presbyopia and serves as a committee member and program director for the International Society of Presbyopia.
Clay Wilemon, Chief Strategy Officer, BRADO - Tues, 10/27 at 8 AM {CLOSED}
Topic | Account Based Marketing (Reaching the Customers you Want and Reducing Dependence on Sales Reps for Lead Generation)
Clay Wilemon currently serves as Chief Strategy Officer at Brado™. He has extensive healthcare marketing experience including helping medical device, biotech, diagnostics, pharmaceutical, and healthcare services companies launch over 500 new medical brands.
Clay is a graduate of Vanderbilt University. He has been a co-founder in two medical device companies and holds a patent for the use of ultrasonic energy in musculoskeletal surgery.
In addition, Clay is a partner in the Visionary Venture Fund and a private investor in medical technology and information technology companies . He also serves on the Board of Directors of OCTANe, a technology focused economic development organization in Southern California.
Goran Matijasevic, Executive Director, Chief Executive Roundtable at UC Irvine - Tues, 10/27 at 8 AM {CLOSED}
Topic | Start Up Resources at a University – Where to go and where to find them?
Goran Matijasevic, MBA, Ph.D., is Executive Director of the UCI Chief Executive Roundtable. In this role, he oversees and advances research collaborations and strategic initiatives and also serves as UCI ambassador, establishing partnerships and opportunities that serve to enhance community connections across all campus interdisciplinary fields. Previously, he was director of research development at the UCI Henry Samueli School of Engineering. Prior to UCI, he worked in research development manager positions at two electronics start-ups. Goran currently serves on the boards of OCTANe and SoCalBio, as well as the advisory board of 2-1-1 Orange County. Goran received his MBA from Pepperdine University and his Ph.D. degree from UC Irvine in Electrical and Computer Engineering.
Audrey Symes, Director of Research Advisory, JLL - Tues, 10/28 at 8 AM {CLOSED}
Topic | How advances in Digitization & Medical Device Development are Facilitating Care During COVID-19 & Beyond
Interested in how Medtech is meeting today’s moment? At the MTIF Breakfast with Experts, hear from Audrey Symes, JLL’s Director of Healthcare, Life Sciences, and Advisory Research, about how advances in both digitization and medical device development are facilitating care during Covid-19 and Beyond. The new era of virtual integration has created innovative opportunities in a number of areas such as digital clinical trials, remote monitoring and compliance, and device approval timelines. How can your company benefit as these developments unfold?
Based in New York, Audrey Symes is responsible for the oversight and expansion of the Research Advisory platform. She is responsible for managing and growing the platform, coordinating efforts nationally across offices, and delivering premium content to clients to help them achieve their highest level of performance.
In her stewardship of the Research Advisory platform, Ms. Symes develops customized analysis of market opportunities, incorporating proprietary data as well as news, events, and economic trends considered within the context of commercial real estate fundamentals. She harnesses the cumulative cross-platform experience of the JLL brokerage and research network to enrich each deliverable with a full complement of institutional knowledge.
John Cox, President & CEO, Somnera - Wed, 10/28 at 8 AM {CLOSED}
Topic | LaunchPad Success Story: Somnera (formerly Fresca Medical)
John joined SOMNERA as President and CEO in 2016, and is a 30 year veteran of the Medical Device Industry. John has held leadership roles in nearly every function, from sales to operations, where he has led numerous products and businesses through development and transformative growth. Prior to joining SOMNERA, John was the Chief Operating Officer of USGI Medical, where he led the development and commercialization of a breakthrough non-invasive surgery platform. He has held senior executive and management roles for several medical device manufacturers such as B. Braun Aesculap, Applied Medical, and U.S. Surgical. John also serves as Chairman and Co-Founder of Retraction Ltd., a Hong Kong-based innovator in minimally invasive surgery. John is named on over 20 US and foreign patents, and earned his MBA with honors from the University of Virginia’s Darden School of Business. Recently, he won Octane’s “Elevator Pitch” contest representing Somnera as a LaunchPad finalist in 2017, and was selected to be the Master of Ceremonies at the 2019 Medical Technology Innovation Forum (MTIF), Orange County’s largest annual Medtech meeting.
Lucien De Busscher, Medical Device Lead Partner for Europe, EY &
Prof. Dr. Pascal Verdonck – MedTech Flanders - CEO - Wed, 10/28 at 8 AM {CLOSED}
Topic | MedTech Trends and Opportunities in Europe
For US medtech companies, big and small, Europe definitely is an attractive market, with highly developed healthcare systems and a strong demand for advanced medical devices and technology. What are the opportunities in that market, what are the trends? What about the regulatory framework and market access? Hot topics, especially now that COVID-19 disrupts supply chains and forces companies to rethink their global organization, bring production closer to local demand.
Join this virtual breakfast session with the experts Lucien De Busscher (Medical Devices Lead Partner in Europe at EY Advisory Services) and Pascal Verdonck (medical technology professor at Ghent University and CEO of MedTech Flanders). Brought to you by the office of Flanders Investment & Trade at the Consulate General of Belgium in Los Angeles.
Mitch Wexler, Managing Partner, Fragomen - Thurs, 10/29 at 8 AM {CLOSED}
Topic | US Visa/Immigration Options for Foreign Start-Ups
Mitch is the Managing Partner of the firm’s Southern California offices, including Irvine, Los Angeles and San Diego.
His practice is quite diverse in that it is comprised of individual high net worth foreign nationals, start up, mid-size, and large multinational companies with regard to all of their work visa/immigration matters.
Mitch’s clients are equally diverse across industry sectors including manufacturing, pharmaceutical, technology, construction, real estate development, entertainment and more.
Mitch is a member of the firm’s national Executive Committee.
He is a California State Bar certified specialist in immigration and nationality law.
Mitch also teaches a regular module on business and investment (including EB-5) immigration law at the University of California Irvine Law School.
Sabing Lee, Partner, Knobbe Martens - Thurs, 10/29 at 8 AM {CLOSED}
Topic | Strategies for Protecting Your Company’s Intellectual Property on a Reduced Budget
Sabing H. Lee's practice includes strategic patent procurement, patent portfolio management, intellectual property due diligence and general counseling on infringement, licensing, international IP protection and post-grant proceedings. Sabing currently represents clients in a wide range of technologies, with an emphasis on medical devices and procedures and materials science.
In the medical device field, Sabing has worked extensively with cardiovascular, orthopedic, wound care and aesthetic technologies. He has been involved in the intellectual property strategy and acquisitions of PercuSurge, Inc. (acquired by Medtronic, Inc.), Flex-Foot, Inc. (acquired by Össur hf.), Endius, Inc. (acquired by Zimmer Holdings, Inc.), ev3 Inc. (acquired by Covidien), IDev Technologies, Inc. (acquired by Abbott), and Tornier NV (merged with Wright Medical Group, Inc.), and CardiAQ Valve Technologies, Inc. (acquired by Edwards Lifesciences Corporation).
Sabing currently serves on the Board of Directors for Octane, an organization that drives technology industry growth and innovation in Orange County by connecting ideas and people with resources and capital.
From 2013-2017, Sabing has been recognized as a Southern California Super Lawyer in Intellectual Property by Super Lawyers magazine. He received Star recognition in the 2012, 2013, 2014, 2015 and 2016 editions of LMG Life Sciences, published by Managing Intellectual Property. Sabing was named to the Daily Journal's list of the Top Intellectual Property Attorneys of 2014, where he was recognized among the Top 25 Portfolio Managers & Patent Prosecutors of Intellectual Property. His accomplishments are detailed in the Awards & Honors section.
Sabing joined the firm in 1997 and became a partner in 2003.
Keith Moore, CEO, Boustead Securities - Thurs, 10/29 at 8 AM {CLOSED}
Topic | SPACs: The Inside Story
Keith Moore, founder and CEO of Boustead Securities, LLC has led Boustead and its affiliates through numerous acquisitions and strategic transactions since 2006. Prior to Boustead, Keith founded numerous technology and service companies. Throughout his career Mr. Moore has served in various executive capacities from micro-cap to Russell 1000 companies, including Activision, Inc., and POPcast Communications Corp.
From 1996 through 2007, Mr. Moore served in Chief Executive and other executive capacities for POPcast Communications Corp. and iTechexpress, Inc., overseeing their respective strategic growth and capital raises. From 1991 through 1996, Mr. Moore served as President, Chief Operating Officer, Chief Financial Officer, Director and Consultant of Activision, Inc. (NASDAQ: ATVI), recognized as the international market leader in videogames. Mr. Moore was a founder of International Consumer Technologies Corp. and was Vice President, Chief Financial Officer and Director since its inception in July 1986 until its merger into Activision in December 1991.
Mr. Moore earned a B.S. in Accounting and a Masters in Finance from Eastern Michigan University.
Holds FINRA Series 7, 63, 24, 79 and 99 licenses.
Scott Phillips, Founder & CEO, StarFish Medical - Fri, 10/30 at 8 AM {CLOSED}
Topic | Game Changing Product Definition Tactics
Scott Phillips will share transformational discoveries and decisions that affected the outcomes of medical device ventures. While leading product development for over 150 medical devices and as many patents, we’ve seen new product initiatives go well and not so well. This session examines lessons distilled from those experiences.
Scott holds a degree in Engineering Physics from the University of British Columbia. Prior to starting StarFish, he worked in diverse areas such as lithium battery development and manufacturing, UV spectroscopy instrumentation and hi-fi audio speakers. Under his leadership StarFish has grown into a diverse professional organization with clients around the world and 100% focus on medical devices. Scott is a Chair of the LifeSciences British Columbia board, Fellow of The Canadian Academy of Engineering, winner of the EY Entrepreneur Of The Year™ 2017 Pacific Awards Technology category, 2017 recipient of the VIATEC Technology Champion award, and volunteers with Junior Achievement, Entrepreneurs Organization, and University of British Columbia.
Linda Villalobos, Human Resources Consultant, Insperity PEO Services - Fri, 10/30 at 8 AM {CLOSED}
Topic | HR Hot Topics & Issues-Bring us your questions for best practices & guidance
HR has become more important than ever for maintaining a company’s revenue potential and growth. From operating during a time of pandemic and civil unrest to maintaining productivity and revenue in a slowed economy, business operators are faced with more challenges than ever. Join this Executive Round Table, and learn how to navigate California’s latest employer compliance, COVID-19 regulations and best practices for managing your greatest asset - your people. Bring us your hot topics, and hear what some of our clients are doing to overcome these common HR challenges;
Linda Villalobos, SPHR-CA, SHRM-SCP, is a Human Resource Consultant at Insperity PEO Services with over 25 years of Human Resource experience. As an Insperity HR Consultant, Linda works with all types of small and medium sized businesses by offering dedicated support and best practice guidance regarding HR matters. Prior to Insperity, Linda was a Human Resource Director in the hospitality industry.
.
Kazuki Sakamoto, Sr. Planner, Teijin &
Hideo Nawata, Sr. Manager, Teijin - Fri, 10/30 at 8 AM {CLOSED}
Topic | Home Healthcare business in Japan and Teijin Pharma’s Activity in the US
Kazuki: Kazuki is a liaison between MCF(Medtech Convergens Fund) and Teijin to foster strategic partnerships and to support collaborative projects. Kazuki joined the MCF team in April 2020 as a project member to support the Medtech fund strategy, portfolio investments, and its strategic LP relationship.
Kazuki is a Senior Planner of Healthcare Business in Teijin’s Strategic Planning Department and has been developing its healthcare business since 2007. His diverse roles in the healthcare field include engineering for a medical device factory, business development for the CPAP business, and M&A activities to acquire a core orthopedic implant business in Japan. Kazuki relocated to the United States in 2019 to support growth initiatives in the Home Healthcare division through investments in early-stage Medtech.